Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK). The collaboration aims to leverage Tempus’ proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics’ oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus’ de-identified multimodal database to support the biotech’s clinical trial designs by focusing on the right patient population with the highest level of demonstrated real-world unmet need. The collaboration will center on powering research spanning Whitehawk Therapeutics’ ADC portfolio, which includes three assets designed to target clinically validated proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI selected by ARPA-H to provide CRO services
- tempus AI Inc Class A call volume above normal and directionally bullish
- Tempus AI Stock (TEM) Spikes 9%— Should You Buy Now?
- Ambry Genetics announces improved EHR-integrated BC risk assessment solution
- Short Report: Tempus AI short interest reaches record high